Deciphera Pharmaceuticals Stock Price, News & Analysis (NASDAQ:DCPH)

$26.59 -1.50 (-5.34 %)
(As of 02/23/2018 09:00 AM ET)
Previous Close$28.09
Today's Range$26.55 - $29.10
52-Week Range$15.15 - $29.98
Volume168,700 shs
Average Volume184,747 shs
Market Capitalization$915.50 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

About Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals logoDeciphera Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing drugs to improve the lives of cancer patients. Its drug candidate includes DCC-2618, DCC-3014 and Rebastinib. Its proprietary kinase switch control inhibitor platform, inhibit the activation of kinases. DCC-2618, an orally administered kinase switch control inhibitor, for the treatment of gastrointestinal stromal tumors (GIST), advanced systemic mastocytosis (ASM), gliomas, including glioblastoma multiforme (GBM), and other solid tumors driven by pan-KIT or PDGFR alpha. DCC-3014 is an orally administered, potent and highly selective inhibitor of colony stimulating factor receptor 1 (CSF1R). Rebastinib is an orally administered, potent and selective inhibitor of the TIE2 immunokinase. Rebastinib binds potently into the switch pocket of TIE2, stabilizing the inhibitory switch and displacing the activation switch to block TIE2 signaling.

Receive DCPH News and Ratings via Email

Sign-up to receive the latest news and ratings for DCPH and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:DCPH
CUSIPN/A
Phone781-209-6400

Debt

Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

Trailing EPSN/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees42
Outstanding Shares32,590,000

Deciphera Pharmaceuticals (NASDAQ:DCPH) Frequently Asked Questions

What is Deciphera Pharmaceuticals' stock symbol?

Deciphera Pharmaceuticals trades on the NASDAQ under the ticker symbol "DCPH."

How were Deciphera Pharmaceuticals' earnings last quarter?

Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) posted its quarterly earnings results on Tuesday, November, 14th. The company reported ($5.85) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by $5.31. View Deciphera Pharmaceuticals' Earnings History.

Where is Deciphera Pharmaceuticals' stock going? Where will Deciphera Pharmaceuticals' stock price be in 2018?

6 analysts have issued 1 year target prices for Deciphera Pharmaceuticals' stock. Their predictions range from $30.00 to $57.00. On average, they expect Deciphera Pharmaceuticals' share price to reach $43.33 in the next twelve months. View Analyst Ratings for Deciphera Pharmaceuticals.

Who are some of Deciphera Pharmaceuticals' key competitors?

When did Deciphera Pharmaceuticals IPO?

(DCPH) raised $101 million in an initial public offering on Thursday, September 28th 2017. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Nomura were co-managers.

When does the company's lock-up period expire?

Deciphera Pharmaceuticals' lock-up period expires on Tuesday, March 27th. Deciphera Pharmaceuticals had issued 7,500,000 shares in its initial public offering on September 28th. The total size of the offering was $127,500,000 based on an initial share price of $17.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who owns Deciphera Pharmaceuticals stock?

Deciphera Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional investors include Viking Global Investors LP (7.35%), Millennium Management LLC (2.24%), Redmile Group LLC (2.10%), Emerald Advisers Inc. PA (1.48%), BlackRock Inc. (1.12%) and ArrowMark Colorado Holdings LLC (0.71%). View Institutional Ownership Trends for Deciphera Pharmaceuticals.

Who sold Deciphera Pharmaceuticals stock? Who is selling Deciphera Pharmaceuticals stock?

Deciphera Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Viking Global Investors LP and Redmile Group LLC. View Insider Buying and Selling for Deciphera Pharmaceuticals.

Who bought Deciphera Pharmaceuticals stock? Who is buying Deciphera Pharmaceuticals stock?

Deciphera Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Sphera Funds Management LTD., Emerald Advisers Inc. PA, Geode Capital Management LLC, Kornitzer Capital Management Inc. KS, Millennium Management LLC, ArrowMark Colorado Holdings LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Deciphera Pharmaceuticals.

How do I buy Deciphera Pharmaceuticals stock?

Shares of Deciphera Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Deciphera Pharmaceuticals' stock price today?

One share of Deciphera Pharmaceuticals stock can currently be purchased for approximately $26.59.

How big of a company is Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals has a market capitalization of $915.50 million. Deciphera Pharmaceuticals employs 42 workers across the globe.

How can I contact Deciphera Pharmaceuticals?

Deciphera Pharmaceuticals' mailing address is 500 TOTTEN POND ROAD, WALTHAM MA, 02451. The company can be reached via phone at 781-209-6400 or via email at [email protected]


MarketBeat Community Rating for Deciphera Pharmaceuticals (DCPH)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  56 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  108
MarketBeat's community ratings are surveys of what our community members think about Deciphera Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Deciphera Pharmaceuticals (NASDAQ:DCPH) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 3.003.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $43.33$43.40$43.40N/A
Price Target Upside: 50.99% upside115.38% upside115.38% upsideN/A

Deciphera Pharmaceuticals (NASDAQ:DCPH) Consensus Price Target History

Price Target History for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ:DCPH) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/16/2018B. RileyInitiated CoverageBuy -> Buy$43.00HighView Rating Details
10/23/2017NomuraInitiated CoverageBuy -> Buy$57.00N/AView Rating Details
10/23/2017Piper Jaffray CompaniesInitiated CoverageOverweight -> Overweight$35.00N/AView Rating Details
10/23/2017InstinetInitiated CoverageBuy$57.00N/AView Rating Details
10/23/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$38.00N/AView Rating Details
10/23/2017JPMorgan Chase & Co.Initiated CoverageOverweight -> Overweight$30.00N/AView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings History and Estimates Chart

Earnings by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ DCPH) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/14/2017Q3 2017($0.55)($5.85)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Deciphera Pharmaceuticals (NASDAQ:DCPH) Earnings Estimates

Current Year EPS Consensus Estimate: $-2.22 EPS
Next Year EPS Consensus Estimate: $-1.81 EPS

Dividends

Dividend History for Deciphera Pharmaceuticals (NASDAQ:DCPH)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 45.99%
Insider Trades by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)
Insider Trades by Quarter for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Deciphera Pharmaceuticals (NASDAQ DCPH) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
10/2/2017New Leaf Venture Management IiMajor ShareholderBuy375,000$17.00$6,375,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Deciphera Pharmaceuticals (NASDAQ DCPH) News Headlines

Source:
DateHeadline
Deciphera Pharma Scores A Sell-Side RecommendationDeciphera Pharma Scores A Sell-Side Recommendation
finance.yahoo.com - February 16 at 4:27 PM
Deciphera Pharmaceuticals (DCPH) Coverage Initiated at B. RileyDeciphera Pharmaceuticals (DCPH) Coverage Initiated at B. Riley
www.americanbankingnews.com - February 16 at 9:52 AM
Deciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of "Buy" from BrokeragesDeciphera Pharmaceuticals Inc (DCPH) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - February 13 at 9:24 PM
Deciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by BidaskClubDeciphera Pharmaceuticals (DCPH) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - February 10 at 12:14 PM
Deciphera Pharmaceuticals (DCPH) Downgraded to "Hold" at Zacks Investment ResearchDeciphera Pharmaceuticals (DCPH) Downgraded to "Hold" at Zacks Investment Research
www.americanbankingnews.com - January 15 at 11:50 PM
Deciphera Pharmaceuticals (DCPH) Rating Increased to Buy at Zacks Investment ResearchDeciphera Pharmaceuticals (DCPH) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - January 9 at 8:58 PM
Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)Deciphera Pharmaceuticals Initiates Phase 3 Clinical Study with DCC-2618 in Patients with Advanced Gastrointestinal Stromal Tumors (“INVICTUS” study)
finance.yahoo.com - January 4 at 8:49 AM
Deciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare ConferenceDeciphera Pharmaceuticals, Inc. to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 3 at 8:02 AM
Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by AnalystsDeciphera Pharmaceuticals Inc (DCPH) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 26 at 12:41 AM
Deciphera Pharmaceuticals (DCPH) Upgraded by Zacks Investment Research to BuyDeciphera Pharmaceuticals (DCPH) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - December 25 at 8:40 PM
Deciphera Pharmaceuticals, Inc. Added to Russell 2000® IndexDeciphera Pharmaceuticals, Inc. Added to Russell 2000® Index
finance.yahoo.com - December 18 at 8:54 AM
Zacks: Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Deciphera Pharmaceuticals Inc (DCPH) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - December 15 at 5:52 AM
Deciphera Pharmaceuticals (DCPH) vs. Its Competitors Head to Head ContrastDeciphera Pharmaceuticals (DCPH) vs. Its Competitors Head to Head Contrast
www.americanbankingnews.com - December 8 at 5:14 PM
 Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from Analysts Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 28 at 5:44 PM
Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Consensus Recommendation of "Strong Buy" from BrokeragesZacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - November 25 at 11:54 AM
Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from AnalystsZacks: Deciphera Pharmaceuticals, Inc. (DCPH) Receives Average Rating of "Strong Buy" from Analysts
www.americanbankingnews.com - November 21 at 11:50 PM
Deciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare ConferenceDeciphera Pharmaceuticals, Inc. to Present at the 29th Annual Piper Jaffray Healthcare Conference
feeds.benzinga.com - November 21 at 8:00 AM
Deciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyDeciphera Pharmaceuticals Reports Data from Ongoing Phase 1 Clinical Study of DCC-2618 at the 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
finance.yahoo.com - November 20 at 6:47 PM
Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.33 Consensus Price Target by BrokeragesZacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.33 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 18 at 8:00 AM
Opening Bell, November 15, 2017Opening Bell, November 15, 2017
finance.yahoo.com - November 16 at 1:22 PM
Deciphera Pharmaceuticals, Inc. (DCPH) Posts Quarterly  Earnings Results, Misses Expectations By $5.30 EPSDeciphera Pharmaceuticals, Inc. (DCPH) Posts Quarterly Earnings Results, Misses Expectations By $5.30 EPS
www.americanbankingnews.com - November 15 at 12:55 PM
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate HighlightsDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
finance.yahoo.com - November 15 at 4:18 AM
Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate HighlightsDeciphera Pharmaceuticals, Inc. Announces Third Quarter 2017 Financial Results and Corporate Highlights
globenewswire.com - November 14 at 6:14 PM
Deciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) to Ring The Nasdaq Stock Market Opening BellDeciphera Pharmaceuticals, Inc. (Nasdaq: DCPH) to Ring The Nasdaq Stock Market Opening Bell
feeds.benzinga.com - November 14 at 11:27 AM
Featured Company News - Deciphera Reported Data Analysis from the Ongoing Phase-1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology SocietyFeatured Company News - Deciphera Reported Data Analysis from the Ongoing Phase-1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
finance.yahoo.com - November 13 at 12:15 PM
Deciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology SocietyDeciphera Pharmaceuticals, Inc. Reports Data Analysis from the Ongoing Phase 1 Clinical Trial of DCC-2618 at the Annual Meeting of The Connective Tissue Oncology Society
finance.yahoo.com - November 10 at 9:10 AM
Deciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-OncologyDeciphera Pharmaceuticals, Inc. to Report Clinical Data with DCC-2618 at the Upcoming 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
finance.yahoo.com - November 6 at 7:09 PM
Analyzing Deciphera Pharmaceuticals (DCPH) & Stemline Therapeutics (STML)Analyzing Deciphera Pharmaceuticals (DCPH) & Stemline Therapeutics (STML)
www.americanbankingnews.com - November 6 at 5:31 PM
Zacks: Brokerages Set $34.33 Price Target for Deciphera Pharmaceuticals, Inc. (DCPH)Zacks: Brokerages Set $34.33 Price Target for Deciphera Pharmaceuticals, Inc. (DCPH)
www.americanbankingnews.com - November 3 at 7:50 PM
Deciphera Pharmaceuticals, Inc.s (DCPH) Quiet Period To End  on November 7thDeciphera Pharmaceuticals, Inc.'s (DCPH) Quiet Period To End on November 7th
www.americanbankingnews.com - November 2 at 1:22 AM
 Deciphera Pharmaceuticals, Inc. (DCPH) Given Average Recommendation of "Strong Buy" by Analysts Deciphera Pharmaceuticals, Inc. (DCPH) Given Average Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - October 31 at 5:38 PM
 Deciphera Pharmaceuticals, Inc. (DCPH) Given Consensus Recommendation of "Strong Buy" by Analysts Deciphera Pharmaceuticals, Inc. (DCPH) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - October 28 at 1:44 AM
Zacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.00 Consensus Price Target by BrokeragesZacks: Deciphera Pharmaceuticals, Inc. (DCPH) Given $34.00 Consensus Price Target by Brokerages
www.americanbankingnews.com - October 25 at 12:50 AM
Nomura Initiates Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)Nomura Initiates Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)
www.americanbankingnews.com - October 23 at 11:58 PM
Piper Jaffray Companies Begins Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)Piper Jaffray Companies Begins Coverage on Deciphera Pharmaceuticals, Inc. (DCPH)
www.americanbankingnews.com - October 23 at 11:58 PM
VYGR Cruises Ahead, APVO On Track, ARDX Continues To Fall, AGRX On WatchVYGR Cruises Ahead, APVO On Track, ARDX Continues To Fall, AGRX On Watch
www.nasdaq.com - October 17 at 11:37 PM
Deciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional SharesDeciphera Pharmaceuticals Announces Closing of Initial Public Offering and Exercise of Option to Purchase Additional Shares
finance.yahoo.com - October 3 at 10:36 AM
Deciphera Pharmaceuticals LLC (DCPH) Major Shareholder Buys $6,375,000.00 in StockDeciphera Pharmaceuticals LLC (DCPH) Major Shareholder Buys $6,375,000.00 in Stock
www.americanbankingnews.com - October 2 at 7:16 PM
Deciphera Pharmaceuticals (DCPH) to Raise $101 Million in IPODeciphera Pharmaceuticals (DCPH) to Raise $101 Million in IPO
www.americanbankingnews.com - September 20 at 1:22 AM

SEC Filings

Deciphera Pharmaceuticals (NASDAQ:DCPH) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Deciphera Pharmaceuticals (NASDAQ:DCPH) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Deciphera Pharmaceuticals (NASDAQ DCPH) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.